Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Reproductive Health Services

 
In compliance with the decisions of the International Conference on Population and Development in 1994 on behalf of the Government of Lebanon, the “Reproductive Health Program” was established at the Ministry of Public Health and supported by the United Nations Population Fund (UNFPA) under the umbrella of primary health care with a clear strategy between 1998 and 2001. The program is still ongoing through its integration within the primary health care department.

The Ministry of Public Health / Primary Health Care Department in collaboration with UNFPA provides various services regarding reproductive health and family planning in agreement with the joint annual work plan signed between the two parties.

The health services can be summarized in the following categories:
  • Family planning
  • Safe motherhood and Newborn Health
  • Diagnostic & Preventive Check-ups
  • Screening for Reproductive system diseases and reproductive tract cancers

I. Reproductive Health Services
The primary health care department provides preventive services in order to improve the health of the family (women, children, youth and men) through:
  • Providing reproductive health medications and supplies through PHC centers, including 57 health centers / clinics outside the primary health care network, and providing reproductive health services to the displaced in order to improve women's health and prevent unwanted pregnancies.
  • Delivering reproductive health information to beneficiaries through awareness and education programs which are provided by the primary health care centers within and outside the centers.
  • Providing equipment that enables early detection of reproductive system diseases (early detection of breast cancer, cervical cancer).
  • Encouraging pregnant women to receive a minimum of 4 visits during pregnancy and one postnatal visit.
  • Developing the capacity of service providers in primary health care centers based on the clinical protocols for reproductive health.
  • Preparing governmental hospitals to receive emergency obstetric cases.
  •  Equipping governmental hospitals to receive high-risk pregnancies.
  •  Capacity building of service providers to deal with survivors of sexual violence and refer them to relevant associations.
  • Capacity building of service providers of provision of equipment for primary health care centers and hospitals to address cases of rape and refer survivors to the relevant associations.
 

II. Antenatal and Postnatal Care Services:
The primary health care department offers as well antenatal and postnatal care services for pregnant Lebanese and non-Lebanese women across Lebanon as part of the reproductive health services. These services were supported by the formulation of the ‘’Service Delivery Guidelines’’, which were followed by consecutive training for primary health care (PHC) centers’ staff across Lebanon upon implementation.

The antenatal and postnatal care services offered by the PHC centers consist of the following:
All pregnant women visiting the centers should receive:
  1.  Minimum of 4 antenatal care services
  2.  2 Echography during pregnancy
  3.  1 postnatal visit
  4.  Coverage of vaccination for newborn of followed up mothers (according to the National Vaccination Calendar)
  5.  Provision of Reproductive Health drugs and supplies to all PHC centers, in addition to 64 Reproductive Health dispensaries supported by International NGOs to serve the displaced Syrians.
 

III. Service Delivery Guidelines for Reporoductive Health Care:
MoPH with the support of UNFPA and in collaboration with the Lebanese Society of Obstetrics & Gynecology (LSOG) launched " The Revised Version of the Service Delivery Guidelines for Reproductive Health" in June 2015, which aimed at improving the knowledge and skills of service providers, in order to ensure the provision of reproductive health services that meet women's, men's and youth's needs in Lebanon.

Accordingly, the first phase of training took place from July to September, with 275 physicians and health care workers, including: 160 paramedical specialties, 88 medical and 27 humanitarian actors.

The training aims to improve the knowledge, skills and confidence of health workers to ensure that reproductive health needs of women, men adults and youth are met in normal setting and in the case of crises.
 
IV. Project Reports:
    1
ATC Name B/G Ingredients Dosage Form Price
D10AF05 NADIXA G Nadifloxacin - 1% 1% Cream 850,652 L.L
S01AE02 NAFLOX G Norfloxacin - 3mg/ml 3mg/ml Drops 370,901 L.L
C04AX21 NAFTILUX B Naftidrofuryl oxalate acid - 200mg 200mg Capsule 533,505 L.L
C04AX21 NAFTIPRAX B Naftidrofuryl hydrogen oxalate - 200mg 200mg Tablet, film coated 614,328 L.L
G03AA12 NAJAT G Drospirenone - 3mg, Ethinylestradiol - 0.03mg Tablet, coated 417,935 L.L
N02AF02 NALBUPHINE RENAUDIN 1% G Nalbuphine HCl - 20mg/2ml 20mg/2ml Injectable solution 1,181,238 L.L
C10AB05 NANOFIB G Fenofibrate - 145mg 145mg Tablet, film coated 1,371,615 L.L
S01GA51 NAPHCON A B Naphazoline HCl - 0.025%, Pheniramine maleate - 0.3% Drops solution 369,557 L.L
M01AE02 NAPROXENE SODIQUE ARROW G Naproxen (sodium) - 550mg 550mg Tablet, film coated, scored 255,330 L.L
R01AB06 NARIX G Xylometazoline HCl - 90mcg/actuation, Carbocisteine - 900mcg/actuation Spray 518,339 L.L
R01AD11 NASACORT AQ B Triamcinolone acetonide - 55mcg/dose 55mcg/dose Spray, suspension 1,003,850 L.L
R01AD11 NASACORT AQ B Triamcinolone acetonide - 55mcg/dose 55mcg/dose Spray, suspension 1,003,850 L.L
R01AD09 NASONEX B Mometasone furoate (monohydrate) - 50mcg/dose 0.05% Spray, suspension 529,474 L.L
R01AD09 NASONEX B Mometasone furoate (monohydrate) - 50mcg/dose 0.05% Spray, suspension 529,474 L.L
A04AA01 NAUSETRON G Ondansetron (HCl dihydrate) - 8mg 8mg Tablet, scored 1,023,880 L.L
A04AA01 NAUSETRON G Ondansetron - 4mg/5ml 4mg/5ml Solution 958,608 L.L
A04AA01 NAUSETRON G Ondansetron - 4mg/5ml 4mg/5ml Solution 802,466 L.L
A03FA03 NAUZEX G Domperidone - 10mg 10mg Tablet 258,530 L.L
L01CA04 NAVELBINE B Vinorelbine (ditartrate) - 20mg 20mg Capsule, soft gelatin 4,048,997 L.L
L01CA04 NAVELBINE B Vinorelbine (ditartrate) - 30mg 30mg Capsule, soft gelatin 6,072,824 L.L
D10AF05 NAXIDERM G Nadifloxacin - 1% 1% Gel 826,783 L.L
N06AB03 NEANXETIN G Fluoxetine (HCl) - 20mg 20mg Capsule 422,351 L.L
C07AB12 NEBILET B Nebivolol HCl - 5mg 5mg Tablet, scored 694,767 L.L
C07BB12 NEBILET PLUS B Nebivolol HCl - 5mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 716,268 L.L
C07BB12 NEBILET PLUS B Nebivolol HCl - 5mg, Hydrochlorothiazide - 25mg Tablet, film coated 716,268 L.L
C07AB12 NEBIVOLOL ARROW LAB G Nebivolol HCl - 5mg 5mg Tablet, quadrisected 1,370,719 L.L
C07AB12 NEBIVOLOL BIOGARAN G Nebivolol HCl - 5mg 5mg Tablet, scored 529,474 L.L
J01DD02 NEGACEF G Ceftazidime (pentahydrate) - 1g 1g Injectable dry powder for solution 4,421,242 L.L
D06BA05 NEO SULFA G Sulfanilamide - 12g 12g Powder 151,022 L.L
R05FA01 NEO-CODION B Codeine Camphosulfonate - 25mg, Sulfogaiacol - 100mg, Grindelia soft extract - 20mg Tablet, coated 258,018 L.L
    1
Sitemap
© Copyrights reserved to Ministry of Public Health 2026